Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis

Journal of Neurology
Xavier MontalbanLudwig Kappos

Abstract

Fingolimod safety and efficacy data in relapsing-remitting multiple sclerosis (RRMS) are available up to 5 years, from an extension of a randomized, placebo-controlled, double-blind, phase 2 study, at a dose higher (5.0/1.25 mg) than the approved dose of 0.5 mg. The objective of the study is to present the end-of-study data (>7 years) from the open-label extension of the phase 2 study. In the core phase (6 months), patients (N = 281) were randomized to placebo or fingolimod 1.25/5 mg. In the extension, placebo patients were randomized to fingolimod 1.25/5 mg. All patients received open-label 1.25 mg fingolimod after month 24 and 0.5 mg after month 60. Clinical visits were performed every 3 months, expanded disability status scale (EDSS) every 6 months and magnetic resonance imaging (MRI) annually. 122 (48.8%) patients completed the extension study; overall fingolimod exposure was 1230.7 patient-years. The most common (>10%) reasons for study discontinuation were adverse events (19.6%) and consent withdrawal (16.4%). Fingolimod treatment for >7 years was associated with sustained low clinical and MRI disease activity. Over 60% of patients remained relapse free and about 80% were free from any MRI activity. Overall annualized rel...Continue Reading

References

May 15, 2001·Journal of Computer Assisted Tomography·S M SmithP M Matthews
Jan 24, 2006·Lancet Neurology·Robert A Bermel, Rohit Bakshi
Sep 15, 2006·The New England Journal of Medicine·Ludwig KapposUNKNOWN FTY720 D2201 Study Group
Jan 6, 2009·Neurology·P O'ConnorUNKNOWN FTY720 D2201 Study Group
Dec 24, 2009·Multiple Sclerosis : Clinical and Laboratory Research·G ComiUNKNOWN FTY720D2201 Study Group
Jan 22, 2010·The New England Journal of Medicine·Ludwig KapposUNKNOWN FREEDOMS Study Group
Jan 22, 2010·The New England Journal of Medicine·Jeffrey A CohenUNKNOWN TRANSFORMS Study Group
Mar 5, 2010·Multiple Sclerosis : Clinical and Laboratory Research·Nicola De StefanoUNKNOWN IMPROVE Study Investigators
Jul 6, 2011·Multiple Sclerosis : Clinical and Laboratory Research·X MontalbanL Kappos
Dec 3, 2013·Multiple Sclerosis : Clinical and Laboratory Research·G IzquierdoL Kappos
Apr 17, 2015·Multiple Sclerosis and Related Disorders·Ludwig KapposGordon Francis

❮ Previous
Next ❯

Citations

Mar 20, 2016·Multiple Sclerosis : Clinical and Laboratory Research·Vanessa CohenDominique Friedmann
Dec 28, 2019·Basic & Clinical Pharmacology & Toxicology·Thomas Lohne NørgaardCharlotte Uggerhøj Andersen
Aug 29, 2017·Expert Opinion on Pharmacotherapy·Katja ThomasTjalf Ziemssen
Sep 26, 2020·Multiple Sclerosis : Clinical and Laboratory Research·Laura FerrèFederica Esposito
Jan 4, 2020·CNS Drugs·Damiano PaolicelliMaria Trojano
Apr 15, 2020·Multiple Sclerosis Journal - Experimental, Translational and Clinical·T DerfussL Kappos

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.